Abivertinib
As of the edition of 20 October 2026, Abivertinib is a small molecule: stopped in 2024; acts on BTK and EGFR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 13, 2 stopped early
- Disease areas
- Cancer; Lungs and airways; Infections; Blood and lymph; Immune system; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
6 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product6 company-target rows are on route A because of Abivertinib.
See the 6 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 2 | 0 | 1 |
| Phase 2 | 7 | 2 | 0 | 0 |
| Phase 3 | 2 | 0 | 0 | 1 |
| All trials | 13 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Hangzhou ACEA Pharmaceutical | Lead sponsor of trials | 2015 to now |
| ACEA Therapeutics | Lead sponsor of trials | 2015 to now |
| Sorrento Therapeutics | Lead sponsor of trials | 2020 to now |